SAT 3247
Alternative Names: SAT-3247Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Satellos Bioscience
- Class Small molecules
- Mechanism of Action Adaptor-associated kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Duchenne muscular dystrophy
- Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury
Most Recent Events
- 13 Nov 2024 Adverse events data from phase-I trial in Duchenne muscular dystrophy (In volunteers) released by Satellos Bioscience
- 01 Oct 2024 Pharmacodynamics and adverse events data from preclinical study in Duchenne muscular dystrophy released by Satellos Bioscience
- 21 Aug 2024 Phase-I for Duchenne muscular dystrophy in Australia (PO) (NCT06565208)